178 related articles for article (PubMed ID: 20122733)
1. Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.
Litzinger MT; Foon KA; Tsang KY; Schlom J; Palena C
Leuk Res; 2010 Oct; 34(10):1351-7. PubMed ID: 20122733
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
Litzinger MT; Foon KA; Sabzevari H; Tsang KY; Schlom J; Palena C
Cancer Immunol Immunother; 2009 Jun; 58(6):955-65. PubMed ID: 19009294
[TBL] [Abstract][Full Text] [Related]
3. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
Palena C; Foon KA; Panicali D; Yafal AG; Chinsangaram J; Hodge JW; Schlom J; Tsang KY
Blood; 2005 Nov; 106(10):3515-23. PubMed ID: 16081691
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.
Heery CR; Palena C; McMahon S; Donahue RN; Lepone LM; Grenga I; Dirmeier U; Cordes L; Marté J; Dahut W; Singh H; Madan RA; Fernando RI; Hamilton DH; Schlom J; Gulley JL
Clin Cancer Res; 2017 Nov; 23(22):6833-6845. PubMed ID: 28855356
[No Abstract] [Full Text] [Related]
5. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).
Shankar P; Schlom J; Hodge JW
Vaccine; 2001 Dec; 20(5-6):744-55. PubMed ID: 11738738
[TBL] [Abstract][Full Text] [Related]
6. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia.
Tolba KA; Bowers WJ; Hilchey SP; Halterman MW; Howard DF; Giuliano RE; Federoff HJ; Rosenblatt JD
Blood; 2001 Jul; 98(2):287-95. PubMed ID: 11435295
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.
Hodge JW; Grosenbach DW; Rad AN; Giuliano M; Sabzevari H; Schlom J
Vaccine; 2001 May; 19(25-26):3552-67. PubMed ID: 11348723
[TBL] [Abstract][Full Text] [Related]
8. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
9. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells.
Biagi E; Yvon E; Dotti G; Amrolia PJ; Takahashi S; Popat U; Marini F; Andreeff M; Brenner MK; Rousseau RF
Hum Gene Ther; 2003 Apr; 14(6):545-59. PubMed ID: 12718765
[TBL] [Abstract][Full Text] [Related]
10. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
11. A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines.
Schlom J; Sabzevari H; Grosenbach DW; Hodge JW
Artif Cells Blood Substit Immobil Biotechnol; 2003 May; 31(2):193-228. PubMed ID: 12751840
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
[TBL] [Abstract][Full Text] [Related]
13. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
14. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
[TBL] [Abstract][Full Text] [Related]
15. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.
Okur FV; Yvon E; Biagi E; Dotti G; Carrum G; Heslop H; Mims MP; Fratantoni JC; Peshwa MV; Li L; Brenner MK
Cytotherapy; 2011 Oct; 13(9):1128-39. PubMed ID: 21745159
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
[TBL] [Abstract][Full Text] [Related]
18. Costimulatory molecules in vaccine design.
Hodge JW; Schlom J
Ernst Schering Res Found Workshop; 2000; (30):23-52. PubMed ID: 10943315
[No Abstract] [Full Text] [Related]
19. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
Hodge JW; Higgins J; Schlom J
Vaccine; 2009 Jul; 27(33):4475-82. PubMed ID: 19450631
[TBL] [Abstract][Full Text] [Related]
20. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors.
Wendtner CM; Kofler DM; Theiss HD; Kurzeder C; Buhmann R; Schweighofer C; Perabo L; Danhauser-Riedl S; Baumert J; Hiddemann W; Hallek M; Büning H
Blood; 2002 Sep; 100(5):1655-61. PubMed ID: 12176885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
